Evogene Ltd. (EVGN)

NASDAQ: EVGN · Real-Time Price · USD

0.6008

-0.0502 (-7.71%)

At close: Aug 14, 2026, 4:00 PM EDT

0.6018

+0.0010 (0.17%)

After-hours: Aug 14, 2026, 7:44 PM EDT

-7.71% (1D)

Market Cap	6.73M -38.9%
Revenue (ttm)	1.84M -72.7%
Net Income	-11.77M
EPS	-1.37
Shares Out	10.41M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	371,957
Open	0.6500
Previous Close	0.6510
Day's Range	0.5905 - 0.6650
52-Week Range	0.3700 - 1.5000
Beta	0.68
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 18, 2026

About EVGN

Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the development and commercialization of castor bean seeds for industrial uses... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1999

Employees 52

Stock Exchange NASDAQ

Ticker Symbol EVGN

Website https://www.evogene.com

Full Company Profile

Financial Performance

In 2025, Evogene's revenue was $3.85 million, a decrease of -30.91% compared to the previous year's $5.58 million. Losses were -$8.49 million, -48.53% less than in 2024.

Financial Statements

News

Evogene Chairman Nir Nimrodi to Join Quarterly Results Call to Address Current Dissident Shareholders Situation

Zoom conference call scheduled for August 18, 2026, at 9:00 AM ET REHOVOT, Israel, Aug. 14, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering company in computational chemist...

2 days ago - PRNewsWire

Evogene Schedules Second Quarter 2026 Financial Results Release

Zoom conference call scheduled for August 18, 2026, 9:00 AM ET REHOVOT, Israel, July 30, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering company in computational chemistry,...

17 days ago - PRNewsWire

Evogene (EVGN) Partners with ELEO for PCSK9 Inhibitor Development

24 days ago - GuruFocus

Evogene and ELEO announce scientific collaboration

Evogene (EVGN) and ELEO, a South Korean biotechnology company focused on developing innovative therapies for chronic and difficult-to-treat diseases, announced a strategic scientific collaboration to ...

24 days ago - TheFly

Evogene Ltd. and ELEO Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule PCSK9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases

Collaboration combines Evogene's AI-driven computational chemistry platform with ELEO's proprietary biological capabilities to accelerate the discovery of novel oral therapies targeting a multi-billio...

24 days ago - PRNewsWire

AgPlenus Launches Novel AI Model for Predicting Antifungal Potency, Expanding ChemPass AI for Ag™ Capabilities

New AI model enables ChemPass AI for Ag™ to identify and prioritize antifungal molecules with a higher probability of biological success at early discovery stages REHOVOT, Israel, July 15, 2026 /PRNe...

4 weeks ago - PRNewsWire

Evogene (EVGN) Partners with Tel Aviv University for Drug Discovery Innovation

5 weeks ago - GuruFocus

Evogene, BCDD announces strategic joint initiative

Evogene (EVGN) and the Blavatnik Center for Drug Discovery, BCDD, at Tel Aviv University announced a strategic joint initiative aimed at accelerating the growth, development, and success of innovation...

5 weeks ago - TheFly

Evogene and Tel Aviv University's Blavatnik Center for Drug Discovery Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery

Supporting Israel's Academic Innovation Ecosystem: BCDD to Provide World-Class Experimental Infrastructure, Evogene to Deliver Computational Chemistry and AI Capabilities REHOVOT, ISRAEL and TEL AVIV,...

5 weeks ago - PRNewsWire

Evogene (EVGN) Achieves Milestone in Collaboration with Google Cloud

7 weeks ago - GuruFocus

Evogene achieves integration of agentic systems with ChemPass AI platform

Evogene (EVGN) announced the successful completion of a significant milestone in its second collaboration with Google (GOOG) Cloud. This milestone marks the integration of agentic computational system...

Other symbols: GOOG GOOGL

7 weeks ago - TheFly

Evogene Announces Major Milestone in Its Collaboration with Google Cloud, Advancing ChemPass AI™ Toward Autonomous Small Molecule Discovery and Optimization

Integration of agentic computational systems enables the early-stage definition of key clinical and biological success criteria, accelerating discovery timelines, improving scalability, and increasing...

7 weeks ago - PRNewsWire

Evogene Slides: Company presentation

Evogene has posted slides in relation to its latest quarterly earnings report, which was published on June 16, 2026.

2 months ago - Filings

Evogene to Present Its Pharma Division Achievements at the BIO International Convention

Conference to be held in San Diego, CA, USA – June 22-25, 2026 REHOVOT, Israel, June 9, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry s...

2 months ago - PRNewsWire

Evogene (EVGN) Completes Phase 1 Trial of BMC128 with Promising Results

2 months ago - GuruFocus

Evogene says Phase 1 clinical study of BMC128 met primary endpoint

Evogene (EVGN) announced the successful completion of the first-in-human Phase 1 clinical study of BMC128, a rationally-designed live bacterial product developed by its subsidiary, Biomica Ltd., in co...

2 months ago - TheFly

Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica

Study Results Demonstrated Favorable Safety Profile and Preliminary Signals of Clinical Activity REHOVOT, Israel, June 2, 2026 /PRNewswire/ -- Evogene Ltd. ("Evogene") (Nasdaq: EVGN) (TASE: EVGN), a p...